Ulcerative Colitis

The interview, the first of three parts to be made available free of charge to all interested investors, can be accessed immediately by visiting http://www.smallcapinsights.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions.

Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense.

One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer.

Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005.

L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives.

Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer.

Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients.

Callisto also has drug...

Read more...